MBI AND IMCERA'S MALLINCKRODT MEDICAL UNIT ANNOUNCE FILING OF NDS FOR ALBUNEX(R)
MBI AND IMCERA'S MALLINCKRODT MEDICAL UNIT
ANNOUNCE FILING OF NDS FOR ALBUNEX(R)
SAN DIEGO, June 18 /PRNewswire/ -- Molecular Biosystems Inc. (NYSE: MB) (MBI) and Mallinckrodt Medical Inc. (a unit of IMCERA Group (NYSE: IMA)) today announced that a New Drug Submission (NDS) for MBI's cardiac ultrasound contrast imaging agent, Albunex(R), has been filed with Canada's Health Protection Branch (HPB). Mallinckrodt Medical Inc., located in St. Louis, has exclusive marketing and distribution rights for Albunex in North and South America.
The NDS, filed earlier this month with the HPB in Ottawa, Ontario is for the use of Albunex with 2-D echocardiography (ultrasound of the heart). A similar submission has been made to the U.S. Food and Drug Administration (FDA) and is currently scheduled to be reviewed by its Radiology Device Advisory Panel on July 14, 1992.
Molecular Biosystems Inc., based in San Diego, is a leader in the development and manufacturing of contrast agents for medical imaging, including ultrasound, magnetic resonance imaging and computed tomography. Its flagship product, Albunex, is currently, in the final stages of the FDA's pre-market approval process. MBI's marketing and distribution partners for Albunex include Mallinckrodt Medical Inc. (a unit of IMCERA Group), Shionogi & Co. Ltd. and Hafslund Nycomed AS.
/CONTACT: Beth Field Wallace (investors) of Molecular Biosystems, 619-452-0681/
(MB IMA) CO: Molecular Biosystems Inc.; Mallinckrodt Medical Inc.;
IMCERA Group ST: California; Missouri IN: MTC SU: JL-EH -- SD004 -- 1424 06/18/92 10:31 EDT